Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec 1;5(12):e2245077.
doi: 10.1001/jamanetworkopen.2022.45077.

Number Needed to Treat in Trials of Targeted Therapies for Advanced Ovarian Cancer

Michele Bartoletti  1 , Sandro Pignata  2 , Domenica Lorusso  3   4 , Francesco Perrone  5 , Diego Zara  1   6 , Fabio Puglisi  1   6
Affiliations

Number Needed to Treat in Trials of Targeted Therapies for Advanced Ovarian Cancer

Michele Bartoletti et al. JAMA Netw Open. .
No abstract available

Plain language summary

This comparative effectiveness study assesses the numbers needed to treat in targeted trials of agents for newly diagnosed ovarian cancer.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Bartoletti reported serving on the advisory board of GSK PLC outside the submitted work. Dr Pignata reported receiving grant funding and personal fees from Roche, Merck and Co Inc, AstraZeneca, and Pfizer Inc and personal fees from Clovis Oncology, GSK PLC, and PharmaMar during the conduct of the study. Dr Lorusso reported receiving grant funding from GSK PLC, Clovis Oncology, Genmab A/S, and Merck and Co Inc, during the conduct of the study and receiving personal fees from Amgen Inc, AstraZeneca, Clovis Oncology, Merck and Co Inc, and PharmaMar outside the submitted work. Dr Perrone reported receiving personal fees from Bayer AG, Ipsen, AstraZeneca, Bristol-Myers Squibb Co, Sandoz International GmbH, Incyte, Celgene Corp, Pierre Fabre, and Janssen-Cilag AG and grant funding to his institution from AstraZeneca, Bayer AG, Roche, Merck and Co Inc, Pfizer Inc, Incyte, Sanofi AS, BioClin, and Tesaro Inc outside the submitted work. Dr Puglisi reported grant funding from Eisai Co Ltd, Roche, and AstraZeneca and personal fees from Eisai Co Ltd, Roche, AstraZeneca, Novartis AG, Eli Lilly and Co, Daiichi Sankyo Co Ltd, Viatris Inc, Amgen Inc, Gilead Sciences Inc, Merck and Co Inc, Pierre-Fabre, Pfizer Inc, Seagen Inc, and Viatris Inc outside the submitted work. No other disclosures were reported.

References

    1. Perren TJ, Swart AM, Pfisterer J, et al. ; ICON7 Investigators . A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365(26):2484-2496. doi: 10.1056/NEJMoa1103799 - DOI - PubMed
    1. Banerjee S, Moore KN, Colombo N, et al. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2021;22(12):1721-1731. doi: 10.1016/S1470-2045(21)00531-3 - DOI - PubMed
    1. González-Martín A, Pothuri B, Vergote I, et al. ; PRIMA/ENGOT-OV26/GOG-3012 Investigators . Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2019;381(25):2391-2402. doi: 10.1056/NEJMoa1910962 - DOI - PubMed
    1. Ray-Coquard I, Pautier P, Pignata S, et al. ; PAOLA-1 Investigators . Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med. 2019;381(25):2416-2428. doi: 10.1056/NEJMoa1911361 - DOI - PubMed
    1. Monk BJ, Parkinson C, Lim MC, et al. A randomized, phase III trial to evaluate rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer (ATHENA–MONO/GOG-3020/ENGOT-ov45). J Clin Oncol. Published online June 6, 2022. doi: 10.1200/JCO.22.01003 - DOI - PMC - PubMed

Publication types